Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
Jiangsu Kanion Pharmaceutical Co. Ltd. is currently overseeing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This single action is assigned to 1 distinct examiner, which centralizes the company's current dialogue with the patent office. Furthermore, the portfolio is active within 1 distinct art unit, indicating a focused administrative presence. This structure avoids the complexity of managing multiple examiners or different art unit standards.
The busiest examiner for this portfolio is BARRERA, IMMACULADA, who is responsible for 1 pending office action. Given that the total number of pending actions is 1, this examiner is managing the entirety of the company's current active prosecution. This direct relationship allows the applicant to focus their legal strategy on the specific tendencies of BARRERA, IMMACULADA. The alignment of 1 pending action with 1 examiner and 1 art unit suggests a streamlined path for the company's intellectual property development. Practitioners should prioritize understanding the specific examination style of this examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRERA, IMMACULADA | 1 | 31.0% | +80.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914868 | RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR, RECOMBINANT PLASMID, AND USE THEREOF | BARRERA, IMMACULADA | 19d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17914868 | RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR, RECOMBINANT PLASMID, AND USE THEREOF | BARRERA, IMMACULADA | 19d |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17914868 | RECOMBINANT NEWCASTLE DISEASE VIRUS AND PREPARATION METHOD THEREFOR, RECOMBINANT PLASMID, AND USE THEREOF | BARRERA, IMMACULADA | 1671 | §103§112Other | Final Rejection | 19d | Pending | Sep 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial